Biological
DC-CIK Immunotherapy
DC-CIK Immunotherapy is a biological therapy with 5 clinical trials. Currently 1 active trials ongoing. Historical success rate of 66.7%.
Total Trials
5
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
66.7%
Based on 2 completed trials
Completion Rate
67%(2/3)
Active Trials
1(20%)
Results Posted
0%(0 trials)
Terminated
1(20%)
Phase Distribution
Ph phase_2
1
20%
Ph not_applicable
2
40%
Ph phase_1
1
20%
Phase Distribution
1
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
1(25.0%)
N/ANon-phased studies
2(50.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
66.7%
2 of 3 finished
Non-Completion Rate
33.3%
1 ended early
Currently Active
1
trials recruiting
Total Trials
5
all time
Status Distribution
Active(1)
Completed(2)
Terminated(1)
Other(1)
Detailed Status
Completed2
Active, not recruiting1
unknown1
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
1
Success Rate
66.7%
Most Advanced
Phase 2
Trials by Phase
Phase 11 (25.0%)
Phase 21 (25.0%)
N/A2 (50.0%)
Trials by Status
active_not_recruiting120%
unknown120%
terminated120%
completed240%
Recent Activity
1 active trials
Showing 5 of 5
completed
Study of Gene Expression Profiling and Immunological Mechanism Affects the Response of Immunotherapy
NCT01884168
completednot_applicable
Gene Expression Profiling of Malignant Tumor Predict the Therapeutic Response of DC-CIK Immunotherapy
NCT01906632
terminatedphase_1
Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma
NCT03393858
unknownnot_applicable
Safety and Efficacy of Immune Therapy for Condyloma
NCT03158480
active_not_recruitingphase_2
Immunotherapy Combined With Capecitabine Versus Capecitabine Monotherapy in Advanced Breast Cancer
NCT02491697
Clinical Trials (5)
Showing 5 of 5 trials
NCT01884168
Study of Gene Expression Profiling and Immunological Mechanism Affects the Response of Immunotherapy
NCT01906632Not Applicable
Gene Expression Profiling of Malignant Tumor Predict the Therapeutic Response of DC-CIK Immunotherapy
NCT03393858Phase 1
Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma
NCT03158480Not Applicable
Safety and Efficacy of Immune Therapy for Condyloma
NCT02491697Phase 2
Immunotherapy Combined With Capecitabine Versus Capecitabine Monotherapy in Advanced Breast Cancer
All 5 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 5